I finally had a chance to listen to the entire video. What a great tour d'horizon for the field. If second half of the talk is about Dr Parney's own research, NWBO is the first company mentioned.
Two negative points are raised:
- Limited resources: according to the speaker, one major problem with bulk antigens is the ability to produce sufficient vaccine. I believe it is missing one key benefit in NWBO's approach: Producing 3 years worth of vaccine takes a small part of a tumor, about the size of a sugar cube if memory serves.
- Hard to test for immune responses against specific tumor antigens. This argument reminds me a bit of the IMUC approach v. the NWBO approach. To me, Linda Powers' talk about "the tumor does not escape" makes more sense and the test will be the data collected during the clinical trials.
So the negative do not seem to have much teeth.
In terms of the positive, Dr. Parney simply states it is the ultimate in personalized medicine. Take the patient's own cells to educate them against the specific tumor antigen.
I'm now curious about the prospect of the combination of anti-PD-1/PD-L1 treatment with DC Vax.
Anyways, a great talk which keeps my confidence in NWBO intact.
Good luck Longs!
-
News 
Market Data 
Discover 
